Research Projects & Grants

For Profit Organization

  • Evaluation of patient outcomes from the kidney allograft outcomes allosure registry (KOAR), Role: Investigator, CareDx, Inc., (10/2024 - 10/2025) Status: Approved
  • A phase 3 prospective, randomized, multi-center, open-label, controlled trial to assess the efficacy and safety of cellular immunotherapy with MDR-101 for induction of immune tolerance in recipients of HLA-matched, living donor kidney transplants, Role: Investigator, Medeor Therapeutics, Inc., (05/2023 - 04/2024) Status: Completed
  • A 24 month, multicenter,randomized, open-label safety and efficacy study of concentration-controlled everolimus with reduced calcineurin inhibitor vs mycophenolate with standard calcineurin inhibitor in denovo renal transplant- advancing renal transplant efficacy and safety outcomes with an eveRolimus- based regimen (TRANSFORM, Jan 2015), Role: Investigator, Novartis Pharmaceuticals Corporation, (02/2018 - 02/2019) Status: Completed
  • A prospective observational trial to evaluate the correlation of T-SPOT® response to CMV infection and T cell-mediated acute graft rejection. The PROTECT Study (PROTECT, May 2015), Role: Investigator, Oxford Immunotec, (07/2017 - 07/2018) Status: Completed
  • Evaluating the use of polymyxin B hemoperfusion in a randomized controlled trial of adults treated for endotoxemia and septic shock (EUPHRATES), Role: Investigator, Spectral Diagnostics Inc., (07/2014 - 07/2015) Status: Completed
  • A phase 3, double-blind, double-dummy, multi-center, prospective, randomized study of the efficacy and safety of LCP-Tacro™ tablets, once daily, compared to Prograf® capsules, twice daily, in combination with mycophenolate mofetil for the prevention of acute allograft rejection in De Novo adult kidney transplant recipients (protocol LCP-Tacro 3002 version 3.0 September 30, 2010), Role: Investigator, LifeCycle Pharma A/S, (10/2013 - 10/2014) Status: Completed
  • A phase 2, randomized, open-label, parallel group, multi-center study to assess the safety and efficacy of alefacept in de novo kidney transplant recipients, Role: Investigator, Astellas Pharma US, Inc., (01/2011 - 01/2012) Status: Completed
  • A phase IV, non interventional, multi-center, open-label, prospective, observational study of the safety, effectiveness, tolerability and compliance of immunosuppressive regimen using mycophenolic acid to treat de novo renal transplant patients in routine clinical practice, Role: Investigator, Novartis Pharmaceuticals Corporation, (05/2010 - 05/2011) Status: Completed
  • A 24-month, multicenter, randomized, open-label non-inferiority study of efficacy and safety comparing concentration-controlled certican in two doses (1.5 and 3.0 g/day starting doses) with reduced neoral versus 1.44g myfortic with standard dose neoral in de novo renal transplant recipients., Role: Investigator, Novartis Pharmaceuticals Corporation, (10/2006 - 10/2007) Status: Completed

Internal

  • Highly Suppressive Regulatory T Cell as a Biomarker for Immunologically Relevant Delayed/Slow Graft Function after Kidney Transplantation, Role: Investigator, LLU Dept. of Surgery, (10/2020) Status: Approved
  • Azotemia in portal hypertension and the role of endothelin-1 and nitric oxide in inducing hepatorenal syndrome and refractory ascites, Role: Investigator, LLU Transplantation Institute, (10/2008 - 10/2009) Status: Completed
  • Clinical outcomes of induction therapies in renal transplant patients, Role: Investigator, LLU Transplantation Institute, (12/2007 - 12/2015) Status: Completed
  • Incidence of Glomerular Disease Post-Kidney Transplant, Role: Investigator, LLU Dept. of Medicine, (10/2024) Status: Approved
  • Assessment of IVIG in highly sensitized patients with panel reactive antigen (PRA) of over 94%., Role: Investigator, LLU Transplantation Institute, (04/2025) Status: Approved

Non-Profit Organization

  • Integration of donor-derived cell-free DNA with HLA-DR+TNFR2+ regulatory T cell in the prediction of acute rejection and graft function after kidney transplantation, Role: Investigator, American Society of Transplant Surgeons, (08/2024 - 08/2025) Status: Approved
  • Belatacept Evaluation of Nephroprotection and Efficacy as First-line Immunosuppresion Trial (BENEFIT), Role: Investigator, Bristol-Myers Squibb Foundation, Inc., (01/2010 - 01/2011) Status: Completed